Glenmark Generics launches topiramate, nebivolvol, mometasone and perindopril in UK

Glenmark has a direct presence in the UK market with first these first products of its own livery

Glenmark Generics (Europe) Ltd has launched its topiramate, nebivolvol, mometasone and perindopril generic versions in UK market.

Glennmark Generic (Europe) Ltd, the  UK-based subsidiary of Glenmark Generics launched topiramate tablets in 25mg, 50mg,100mg, 200mg strengths in UK on September 24, 2009 which was day-1 of patent expiry in the UK market.

Glenmark’s anticonvulsant drug topiramate is the generic of Ortho-McNeil Neurologics and Noramco, Inc – divisions of Johnson & Johnson –brand name drug Topamax.

Topiramate has market size of Euro 21 million, according to IMS Health.

Glenmark Generic launched anti-hypertensive drug nebivolol 5mg tablets. Nebivolvol has a market size of Euro 6.8 million. Mylan Laboratories licensed the U.S. and Canadian rights to nebivolol from Janssen Pharmaceutica N.V. in 2001.

Glenmark Generic introduced blood pressure drug perindopril tablets in three strengths – 2mg, 4mg, 8mg -in UK market. peridopril has a market size of Euro 88 million.

Mometasone is launched in an ointment 0.1% in 30gms,100gms packs.Mometasone is the generic version of Schering-Plough Elocon. Mometasone is used for the treatment of skin disorders like psoriasis and eczema and has an estimated market size of Euro 3.5 million.

Glenmark is the only company marketing the generic mometasone ointment product in the UK market while for perindopril, the launch is an addition to third party business existing since last year when the product was launched, the company informed in a press release.

Glenmark Generic has been launching the products for the first time in its own livery in the UK.

All these products will be sold directly by the UK subsidiary and through it’s own front end.
Generic launches in UK will increasingly supplement the revenue stream for Glenmark Generics  which has traditionally relied on dossier licensing and third party commercial supplies to leading generic companies operating in Europe.

“We will continue to expand our product range in the coming months by developing products where we are vertically integrated and also develop products & packs that will help with patient compliance to therapeutic regimes,” stated Terrance Coughlin, chief executive officer, Glenmark Generics Limited.

Glenmark Generics Limited (GGL) is a subsidiary of Mumbai, India-based Glenmark Pharmaceuticals Limited (Glenmark). GGL has an established presence in North America, EU and Argentina and maintains marketing front-ends in these countries.

Glenmark Generics primarily sells its FDF products in the United States and the European Union  as well as its oncology FDF products in South America.

Glenmark Generics supplies APIs to customers in approximately 65 countries, including the US, various countries in the EU, South America and India.

Glenmark Pharmaceuticals Ltd has eight molecules in various stages of clinical development and is primarily focused in the areas of inflammation (asthma/COPD, rheumatoid arthritis etc.), metabolic disorders (diabetes, obesity, etc.) and neuropathic pain and inflammatory pain.

Glenmark has a significant presence in branded generics markets across emerging economies including India.

Glenmark Pharma, along with its subsidiary has twelve manufacturing facilities in four countries and has five R&D centres.

Glenmark is planning to launch an initial public offering or sell shares of Glenmark Generics Ltd. to private equity firms to minimise the huge debt burden by the end of March, Glenmark’s chief executive officer Glenn Saldanha was quoted as saying in recent reports.

Glenmark has already initiated proceeding to list Glenmark generics in Indian bourses.